Free Trial

McKesson (MCK) Stock Forecast & Price Target

McKesson logo
$597.68 -5.83 (-0.97%)
Closing price 02/21/2025 03:59 PM Eastern
Extended Trading
$597.95 +0.27 (+0.05%)
As of 02/21/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

McKesson - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
14

Based on 16 Wall Street analysts who have issued ratings for McKesson in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for MCK.

Consensus Price Target

$645.79
8.05% Upside
According to the 16 analysts' twelve-month price targets for McKesson, the average price target is $645.79. The highest price target for MCK is $688.00, while the lowest price target for MCK is $579.00. The average price target represents a forecasted upside of 8.05% from the current price of $597.68.
Get the Latest News and Ratings for MCK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for McKesson and its competitors.

Sign Up

MCK Analyst Ratings Over Time

TypeCurrent Forecast
2/24/24 to 2/23/25
1 Month Ago
1/25/24 to 1/24/25
3 Months Ago
11/26/23 to 11/25/24
1 Year Ago
2/24/23 to 2/24/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
13 Buy rating(s)
8 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$645.79$646.14$631.57$511.54
Forecasted Upside8.05% Upside9.24% Upside2.41% Upside-0.91% Downside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

MCK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MCK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

McKesson Stock vs. The Competition

TypeMcKessonMedical CompaniesS&P 500
Consensus Rating Score
2.94
2.82
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside8.05% Upside29,256.97% Upside14.35% Upside
News Sentiment Rating
Positive News

See Recent MCK News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/6/2025Evercore ISI
2 of 5 stars
Elizabeth Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$650.00 ➝ $675.00+14.97%
1/10/2025Citigroup
3 of 5 stars
Daniel Grosslight
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$713.00 ➝ $677.00+15.15%
1/6/2025Bank of America
3 of 5 stars
 Lower TargetBuy ➝ Buy$680.00 ➝ $650.00+11.48%
12/17/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$612.00 ➝ $642.00+14.35%
12/13/2024Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$535.00 ➝ $641.00+10.71%
12/4/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Valiquette
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$630.00+1.95%
11/7/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/7/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform$531.00 ➝ $688.00+25.25%
10/7/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$665.00 ➝ $630.00+29.78%
9/25/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$623.00 ➝ $579.00+20.99%
8/21/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$656.00 ➝ $661.00+19.54%
8/8/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$596.00 ➝ $616.00+12.78%
6/24/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$570.00 ➝ $670.00+11.10%
5/8/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$563.00 ➝ $652.00+19.74%
5/8/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$620.00 ➝ $630.00+14.00%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
8/11/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$450.00 ➝ $485.00+11.71%
5/9/202358.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:58 AM ET.


Should I Buy McKesson Stock? MCK Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, February 16, 2025. Please send any questions or comments about these McKesson pros and cons to contact@marketbeat.com.

McKesson
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in McKesson Co.:

  • The current stock price of McKesson Co. is $593.82, which is significantly below the average price target of $645.79, indicating potential for price appreciation.
  • McKesson Co. has a consensus rating of "Moderate Buy," suggesting that analysts believe the stock is a good investment opportunity.
  • The company recently announced a quarterly dividend of $0.71 per share, providing a steady income stream for investors, with an annualized yield of 0.48%.
  • Institutional investors own 85.07% of McKesson Co.'s stock, indicating strong confidence from large financial entities in the company's future performance.
  • Despite a recent earnings miss, analysts forecast an EPS of 32.69 for the current year, suggesting growth potential in profitability.

McKesson
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in McKesson Co. for these reasons:

  • Insider selling has been observed, with executives selling 1,346 shares worth $795,275 in the last three months, which may indicate a lack of confidence in the stock's short-term performance.
  • The company reported a negative return on equity of 181.26%, which suggests that it is not effectively generating profit from its equity investments.
  • McKesson Co. has a relatively low net margin of 0.82%, indicating that it retains a small portion of revenue as profit, which could limit growth and investment opportunities.
  • The stock has experienced volatility, with a 1-year low of $464.42 and a high of $637.51, which may deter risk-averse investors.
  • Recent insider transactions show a 15.17% decrease in the position of an executive vice president, which could raise concerns about the company's internal outlook.

MCK Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for McKesson is $645.79, with a high forecast of $688.00 and a low forecast of $579.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last twelve months. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MCK shares.

According to analysts, McKesson's stock has a predicted upside of 8.05% based on their 12-month stock forecasts.

McKesson has been rated by research analysts at Bank of America, Citigroup, Evercore ISI, Mizuho, Morgan Stanley, and Wells Fargo & Company in the past 90 days.

Analysts like McKesson more than other "medical" companies. The consensus rating score for McKesson is 2.94 while the average consensus rating score for "medical" companies is 2.82. Learn more on how MCK compares to other companies.


This page (NYSE:MCK) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners